由纳米体对手对μ-阿片类受体向的结构基础
Jun Yu1, Amit Kumar2, Xuefeng Zhang1
1Department of Molecular and Cellular Biology, University of Geneva, Geneva, Switzerland.
Nature communications
|October 9, 2024
概括
研究人员开发了NbE,这是一种选择性地准微型阿片类受体 (microOR) 的纳米体,并充当对手. 这一发现通过探索微OR调制,为开发更安全的疼痛治疗方法提供了一种新的方法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 结构生物学 结构生物学
- 生物化学 生物化学
背景情况:
- 微型阿片类受体 (microOR) 是阿片类止痛药的关键点.
- 目前的阿片类药物具有严重的副作用,推动了对新型调节器的需求.
- 像纳米体这样的生物学物质在针对GPCR的小分子上具有优势.
研究的目的:
- 描述一种新型的纳米体,NbE,可以选择性地结合和对抗微型阿片类受体.
- 通过NbE阐明微OR对抗性的分子机制.
- 探索NbE作为开发新的微OR向治疗方法的基础.
主要方法:
- 作为细胞外微OR连接体的NbE的功能性表征.
- 确定NbE-microOR复合体的冷电子显微镜 (cryo-EM) 结构.
- 基于NbE的结构设计和合成类型.
主要成果:
- NbE选择性地与微OR结合并对抗它.
- 冷-EM结构显示了NbE独特的连接体结合模式,涉及与orthosteric口袋和细胞外环的相互作用.
- 在微OR中插入NbE的β-hairpin循环是其对抗性的关键.
- 来自NbE的类类似物重复了其对抗性活性.
结论:
- 纳米体可以独特地与G蛋白结合受体 (GPCRs) 进行交互,如微OR.
- NbE为microOR对抗提供了结构基础,并作为开发新型低分子量microOR配体的模板.
- 这项研究为开发更安全,更有选择性的针对微型阿片类药物受体系统的治疗方法开辟了道路.
相关概念视频
Opioid Receptors: Overview
555
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
555
Drug-Receptor Interaction: Antagonist
2.8K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
2.8K
Analgesia and Pain Management
540
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
540
Drug-Receptor Interaction: Agonist
2.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K
Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K
Drug-Receptor Interactions
5.0K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.0K


